HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial

摘要

BackgroundLittle is known regarding HIV disease outcomes among individuals who become infected with HIV while receiving antiretroviral medications for prevention. We compared HIV disease parameters among women who seroconverted while receiving tenofovir-containing oral or vaginal pre-exposure prophylaxis (PrEP) to placebo.